Xponance Inc. Increases Stock Position in Integer Holdings Co. (NYSE:ITGR)

Xponance Inc. boosted its holdings in Integer Holdings Co. (NYSE:ITGR) by 9.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,396 shares of the medical equipment provider’s stock after purchasing an additional 207 shares during the quarter. Xponance Inc.’s holdings in Integer were worth $318,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Intech Investment Management LLC lifted its position in Integer by 51.1% during the 4th quarter. Intech Investment Management LLC now owns 11,767 shares of the medical equipment provider’s stock worth $1,559,000 after acquiring an additional 3,980 shares during the period. Cibc World Markets Corp purchased a new stake in shares of Integer during the fourth quarter worth approximately $413,000. Corient Private Wealth LLC grew its position in Integer by 6.4% in the 4th quarter. Corient Private Wealth LLC now owns 1,969 shares of the medical equipment provider’s stock valued at $261,000 after buying an additional 118 shares during the last quarter. Royce & Associates LP grew its position in Integer by 31.9% in the 4th quarter. Royce & Associates LP now owns 61,759 shares of the medical equipment provider’s stock valued at $8,184,000 after buying an additional 14,919 shares during the last quarter. Finally, Swiss National Bank increased its stake in Integer by 0.8% in the 4th quarter. Swiss National Bank now owns 65,900 shares of the medical equipment provider’s stock valued at $8,733,000 after buying an additional 500 shares during the period. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Stock Performance

Shares of ITGR stock opened at $117.74 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.09 and a current ratio of 2.95. The stock has a market cap of $3.96 billion, a PE ratio of 35.04, a P/E/G ratio of 1.72 and a beta of 1.24. Integer Holdings Co. has a 1 year low of $107.11 and a 1 year high of $146.36. The stock has a fifty day moving average price of $130.95 and a 200 day moving average price of $132.02.

Integer (NYSE:ITGR) last released its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.46 by ($0.03). The firm had revenue of $449.50 million for the quarter, compared to analyst estimates of $446.28 million. Integer had a return on equity of 11.65% and a net margin of 6.92%. Sell-side analysts forecast that Integer Holdings Co. will post 6.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ITGR. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Integer in a report on Tuesday, December 3rd. Oppenheimer cut Integer from an “outperform” rating to a “market perform” rating in a research report on Friday, February 21st. Truist Financial raised their price target on Integer from $147.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. KeyCorp upped their price objective on Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Finally, Citigroup raised their target price on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Integer currently has a consensus rating of “Moderate Buy” and an average target price of $149.00.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.